Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Chromadex (CDXC)
NASDAQ:CDXC
Holding CDXC?
Track your performance easily
CDXC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.36 - $7.97
Previous Close$5.49
Volume1.20M
Average Volume (3M)1.27M
Market Cap
$419.34M
Enterprise Value$422.24M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$2.90M
Price to Earnings (P/E)290.5
Beta1.31
Next Earnings
Mar 05, 2025EPS Estimate
$0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding76,383,267
10 Day Avg. Volume704,456
30 Day Avg. Volume1,266,166
Standard Deviation0.36
R-Squared0.10
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)12.20
Price to Sales (P/S)4.57
Price to Cash Flow (P/CF)30.00
P/FCF Ratio30.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.79
Enterprise Value/Gross Profit8.32
Enterprise Value/Ebitda1.24K
Forecast
1Y Price Target
$7.60Price Target Upside38.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Chromadex News
PremiumCompany Announcements
ChromaDex Reports Strong Q3 2024 Financial Results
PremiumCompany Announcements
Chromadex Reports Strong Q3 2024 with 31% Sales Increase
Ownership Overview
30.42% Insiders
6.70% Mutual Funds
7.12% Other Institutional Investors
48.58% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CDXC FAQ
What was Chromadex’s price range in the past 12 months?
Chromadex lowest stock price was $1.36 and its highest was $7.97 in the past 12 months.
What is Chromadex’s market cap?
Currently, no data Available
When is Chromadex’s upcoming earnings report date?
Chromadex’s upcoming earnings report date is Mar 05, 2025 which is in 73 days.
How were Chromadex’s earnings last quarter?
Chromadex released its earnings results on Oct 31, 2024. The company reported $0.029 earnings per share for the quarter, beating the consensus estimate of $0.006 by $0.023.
Is Chromadex overvalued?
According to Wall Street analysts Chromadex’s price is currently Undervalued.
Does Chromadex pay dividends?
Chromadex does not currently pay dividends.
What is Chromadex’s EPS estimate?
Chromadex’s EPS estimate is $0.02.
How many shares outstanding does Chromadex have?
Chromadex has 76,383,270 shares outstanding.
What happened to Chromadex’s price movement after its last earnings report?
Chromadex reported an EPS of $0.029 in its last earnings report, beating expectations of $0.006. Following the earnings report the stock price went up 67.908%.
Which hedge fund is a major shareholder of Chromadex?
Among the largest hedge funds holding Chromadex’s share is Gamco Investors, Inc. ET AL. It holds Chromadex’s shares valued at 522K.
---
Chromadex Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.60 (38.43% Upside)
$7.60 (38.43% Upside)
Blogger Sentiment
Bullish
CDXC Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 90.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $21.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 8.6%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
283.91%
12-Months-Change
Fundamentals
Return on Equity
4.82%
Trailing 12-Months
Asset Growth
5.68%
Trailing 12-Months
Company Description
Chromadex
Chromadex Corp. is a nutraceutical company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It operates through the following segments: Ingredients, Consumer Products, and Analytical Reference Standards and Services. The Ingredients segment offers NIAGEN in an ingredient form to partners. The Consumer Products segment sells TRU NIAGEN to improve health by safely raising NAD levels. The Analytical Reference Standards and Services segment provides product regulatory approval and scientific advisory services to the clients in the food, supplement, and pharmaceutical industries. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in September 1999 and is headquartered in Irvine, CA.
---
CDXC Company Deck
---
CDXC Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant positive financial performance, with record revenue and growth primarily driven by NIAGEN and e-commerce sales. The company also made strategic advancements with the NIAGEN+ product line and FDA communications. However, challenges in the Hong Kong market and increased legal expenses were noted as lowlights.Read More>---
CDXC Stock 12 Month Forecast
Average Price Target
$7.60
▲(38.43% Upside)
Technical Analysis
Helius Medical Technologies
―
Cassava Sciences
―
Aethlon Medical
―
Relmada Therapeutics
―
Best Analysts Covering CDXC
1 Year
1 Year Success Rate
6/10 ratings generated profit
1 Year Average Return
+48.82%
reiterated a buy rating 17 days ago
Copying Sean McGowan's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +48.82% per trade.
---